New mPEG-coated Nanoparticles Clear Slowly from

New mPEG-coated Nanoparticles Clear Slowly from Blood Circulation
At the April 2017 Annual Meeting of the American Association for Cancer Research, we first reported our long-circulating mPEG-coated PrecisionMRX® superparamagnetic nanoparticles. Since then, we've refined the formulation, added manufacturing capacity, and continued to study the capabilities of these remarkable nanoparticles. In a more recent preclinical study, reported earlier in September at the 2017 World Medical Imaging Congress, PK data showed that after 24 hours in circulation, only 10% of injected particles are immobilized in liver and therefore yielding non-specific signal (see chart). This is good news for clinical researchers and other life scientists performing in vivo and in vitro applications such as magnetic particle imaging, ultrasound imaging, hyperthermia, immunoassays, and cell enrichment assays. Designed for stability in complex media, the new nanoparticles are composed of a 25 nm iron oxide core, coated with a monolayer of oleic acid, a monolayer of amphiphilic polymer, and a monolayer of methoxypolyethylene glycol. mPEG-coated PrecisionMRX nanoparticles are now available in 5 and 10 mg vials. Get 15% off when you order before October 31 — enter coupon code "INTRO" when you check out.
Pre-clinical Data Presented at the 2017 World Medical Imaging Congress Move MagSense™ Closer to the Clinic
"Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry" is the title of a poster presented by Erika Vreeland, PhD, at the 2017 World Medical Imaging Congress. The poster data, showing high sensitivity and the selective ability of tumor-targeting MagSense nanoparticles to discriminate between HER2-overexpressing and non-overexpressing cancer cells in mice, contribute to the evidence Imagion Biosystems is building in support of the company's plan for first-in-human clinical trials.

Download the poster "Specific detection of HER-2 positive tumors in mice using superparamagnetic relaxometry (SPMR)."

Ian Shipway, Director of Engineering

Say "hello" to Imagion Biosystems' Director of Engineering, Ian Shipway, who joined the company in August. Mr. Shipway will apply his deep experience in ultrasound imaging and medical instrumentation engineering to the development of a safe, effective, manufacturable, and regulation-compliant clinical MagSense imaging system. Upon being discovered through our recruitment program, Mr. Shipway was "immediately very excited" about the possibility of joining Imagion Biosystems, citing the lure of groundbreaking technology, the opportunity to improve lives by enabling earlier cancer detection, the company's successful pre-clinical development program, and the strong team of employees and collaborators as factors contributing to his interest. As an Honors graduate of the University of Western Australia's School of Electrical Engineering, Mr. Shipway has chosen to focus his career on the medical device industry because it affords him with opportunities to do work that can make positive changes in people's lives.